Drug Trial Radar · NCT05562609
Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40,000
Planned (sponsor's estimate)
Start
Apr 22, 2024
Primary completion
Sep 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UNITAID
- First posted
- Oct 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Heavy bleeding after childbirth, known as a postpartum haemorrhage (PPH), causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The I'M WOMAN trial is a research study to see whether giving TXA just before childbirth will stop women developing PPH. The trial will assess the effects of intramuscular (IM) and intravenous (IV) tranexamic acid on PPH, side effects and other important maternal health outcomes.
Conditions
- Postpartum Hemorrhage
Interventions
Tranexamic acidDrug
Ampoules and packaging for all arms will be identical in appearance.
PlaceboOther
Ampoules and packaging for all arms will be identical in appearance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Risk of Postpartum haemorrhageTime frame: within 24 hours of childbirth
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mbeya Regional Referral Hospital
Mbeya, Tanzania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.